Related Experiment Videos
Hepatitis C: How should we manage the patient?
1Department of Medicine A, Imperial College, St Mary's Hospital, London W2 1NY, UK. j.main@imperial.ac.uk
Journal of Viral Hepatitis
|September 11, 2004
Summary
Hepatitis C (HCV) infection diagnosis and management require careful patient assessment. Initial consultations are key for understanding patient background, staging liver disease, and planning treatment, including interferon and ribavirin therapy.
Area of Science:
- Hepatology
- Infectious Diseases
- Internal Medicine
Background:
- Hepatitis C Virus (HCV) infection presents a spectrum of clinical issues, from asymptomatic cases with minor liver damage to advanced cirrhosis and hepatocellular carcinoma.
- Diagnosis can be unexpected or anticipated based on patient risk factors and prior knowledge.
- Physician-patient communication varies, requiring tailored education and information gathering.
Purpose of the Study:
- To outline the importance of the initial patient consultation in managing Hepatitis C Virus (HCV) infection.
- To emphasize the role of patient history and physical examination in assessing liver disease.
- To guide the decision-making process for subsequent investigations and treatment strategies.
Main Methods:
- Initial patient consultation to gather medical history and assess risk factors.
- Physical examination to evaluate clinical signs of liver disease.
- Organizing confirmatory diagnostic tests and staging investigations.
Main Results:
- The initial consultation provides crucial information for patient assessment and disease staging.
- Physical examination offers valuable insights into the progression of liver damage.
- Diagnostic workup guides the determination of appropriate management, including combination therapy.
Conclusions:
- Effective management of Hepatitis C Virus (HCV) infection hinges on a thorough initial patient assessment.
- Understanding the patient's background and clinical status is vital for tailoring treatment plans.
- The consultation facilitates informed decisions regarding eligibility for therapies like interferon and ribavirin combination therapy.